AndresForero-TorresMD

Hematology • Birmingham, AL

Professor, Medicine, University of Alabama School of Medicine

Join to view full profile

Dr. Forero-Torres is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Forero-Torres' full profile

Already have an account?

Office
2000 6th Ave S
Birmingham, AL 35233
Phone+1 205-934-9999
Is this information wrong?

Summary

Director, Clinical Studies Shared Facility Comprehensive Cancer Center

Education & Training

University of Alabama Medical CenterFellowship, Hematology and Medical Oncology, 1988 - 1991
Pontifical Xavierian UniversityClass of 1982

Certifications & Licensure

AL State Medical License 2001 - 2024

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2010-2014
America's Top Doctors for Cancer Castle Connolly, 2009-2013
Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Most Compassionate Doctor American Registry
Join now to see all

Clinical Trials

BMS-247550 in Treating Patients With Metastatic Colorectal Cancer Start of enrollment: 2002 Feb 01
Terminated
Phase 2
Radiolabeled Monoclonal Antibody in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Start of enrollment: 2001 Aug 01
Terminated
Phase 1
Open Label Trial for Post-Menopausal Women With Newly Diagnosed Operable Breast Cancer Start of enrollment: 2005 Jun 01
Completed
Phase 2
Safety and Efficacy Study of an Anti-CD20 Monoclonal Antibody (AME-133v) to Treat Non-Hodgkin's Lymphoma Start of enrollment: 2006 Jul 01
Completed
Phase 1
Forodesine in the Treatment of Cutaneous T-Cell Lymphoma Start of enrollment: 2007 Jul 01
Completed
Phase 2
Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy Start of enrollment: 2011 Jul 01
Completed
Phase 1
A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma Start of enrollment: 2011 Aug 01
Completed
Phase 2
Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer Start of enrollment: 2013 Mar 07
Completed
Phase 2
A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL) Start of enrollment: 2012 Oct 31
Completed
Phase 2
ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas Start of enrollment: 2013 Jan 31
Completed
Phase 3
A Safety Study of SGN-CD19A for B-Cell Lymphoma Start of enrollment: 2013 Feb 01
Completed
Phase 1
Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies Start of enrollment: 2013 Mar 14
Terminated
Phase 2
Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma Start of enrollment: 2013 Jun 01
Completed
Phase 1, Phase 2
A Pharmacodynamics Pre-surgical Study of LEE011 in Early Breast Cancer Patients (MONALEESA-1) Start of enrollment: 2013 Oct 01
Terminated
Phase 2
Paclitaxel and BKM120 Before Surgery in Treating Patients With Stage II or III Estrogen Receptor-Positive and HER2-Negative Breast Cancer Start of enrollment: 2014 Aug 01
Withdrawn
Phase 2
A Safety Study of SGN-LIV1A in Breast Cancer Patients Start of enrollment: 2013 Oct 22
Completed
Phase 1
Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast Cancer Start of enrollment: 2014 May 01
Completed
Phase 2
Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer Start of enrollment: 2014 May 19
Completed
Phase 1
A Safety Study of SGN-CD19B in Patients With B-cell Non-Hodgkin Lymphoma Start of enrollment: 2016 Feb 01
Terminated
Phase 1
Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma Start of enrollment: 2018 Nov 28
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery.
Elias, A., Kathy S Albain, Christina Yau, Emanuel F Petricoin, Denise M Wolf, Julie E Lang, A Jo Chien, Tufia Haddad, Andres Forero-Torres, Anne M Wallace, Henry Kapla...> ;Clinical Cancer Research. 2024 Feb 16
Race, Gene Expression Signatures, and Clinical Outcomes of Patients With High-Risk Early Breast Cancer.
Beverly Kyalwazi, Christina Yau, Michael J Campbell, Toshio F Yoshimatsu, A Jo Chien, Anne M Wallace, Andres Forero-Torres, Lajos Pusztai, Erin D Ellis, Kathy S Albain...> ;JAMA Network Open. 2023 Dec 1
2 citations
A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2+ Breast Cancer.
Jamunarani Veeraraghavan, Carolina Gutierrez, Carmine De Angelis, Robert Davis, Tao Wang, Tomas Pascual, Pier Selenica, Katherine Sanchez, Hiroaki Nitta, Monesh Kapadi...> ;Clinical Cancer Research. 2023 Aug 15
10 citations
Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy.
Mark Jesus M Magbanua, Lamorna Brown Swigart, Ziad Ahmed, Rosalyn W Sayaman, Derrick Renner, Ekaterina Kalashnikova, Gillian L Hirst, Christina Yau, Denise M Wolf, Wen...> ;Cancer Cell. 2023 Jun 12
3 citations
Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial.
Kala Visvanathan, Leslie Cope, Mary Jo Fackler, Michael Considine, Lori Sokoll, Lisa A Carey, Andres Forero-Torres, James N Ingle, Nancy U Lin, Rita Nanda, Anna Maria ...> ;Clinical Cancer Research. 2023 Feb 16
1 citations
A phase I/II study of preoperative letrozole, everolimus, and carotuximab in stage 2 and 3 hormone receptor-positive and Her2-negative breast cancer.
Christos Vaklavas, Erica M Stringer-Reasor, Ahmed M Elkhanany, Kevin J Ryan, Yufeng Li, Charles P Theuer, Edward P Acosta, Shi Wei, Eddy S Yang, William E Grizzle, And...> ;Breast Cancer Research and Treatment. 2023 Apr 1
6 citations
Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer.
Julie E Lang, Andres Forero-Torres, Douglas Yee, Christina Yau, Denise Wolf, John Park, Barbara A Parker, A Jo Chien, Anne M Wallace, Rashmi Murthy, Kathy S Albain, Er...> ;NPJ Breast Cancer. 2022 Dec 1
Phase 1 Study Evaluating Pharmacokinetics and Tolerability of Ofatumumab Combined With Bendamustine in Patients With Indolent B-Cell Non-Hodgkin's Lymphoma.
Andres Forero-Torres, Jason Claud Chandler, Swaminathan P Iyer, Abraham S Kanate, Michelle Quinlan, Petra Hoever, Miguel Izquierdo, Jaclyn Davis, Sumit Madan> ;Clinical Pharmacology in Drug Development. 2022 Sep 1
1 citations
Real-world outcomes among patients with HER2+ metastatic breast cancer with brain metastases.
Kendra DeBusk, Chiemeka Ike, Nicolas Lindegger, Naomi Schwartz, Andy Surinach, Yutong Liu, Andres Forero-Torres> ;Journal of Managed Care & Specialty Pharmacy. 2022 Jun 1
8 citations
Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TB...
Romualdo Barroso-Sousa, Paolo Tarantino, Nabihah Tayob, Chau Dang, Denise A Yardley, Steven J Isakoff, Vicente Valero, Meredith Faggen, Therese Mulvey, Ron Bose, Jiani...> ;NPJ Breast Cancer. 2022 Feb 16
34 citations
Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial.
Elias, A., Amy S. Clark, Christina Yau, Denise M. Wolf, Emanuel F. Petricoin, Laura J. van't Veer, Douglas Yee, Stacy L. Moulder, Anne M. Wallace, A. Jo Chien, Claudin...> ;Nature Communications. 2021 Nov 5
12 citations
Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer
Douglas Yee, Claudine Isaacs, Denise M. Wolf, Christina Yau, Paul Haluska, Karthik V. Giridhar, Andres Forero-Torres, A. Jo Chien, Anne M. Wallace, Lajos Pusztai, Kath...> ;NPJ Breast Cancer. 2021 Oct 5
37 citations
Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clini...
W. Fraser Symmans, Christina Yau, Yunn Yi Chen, Ronald Balassanian, Molly Klein, Lajos Pusztai, Rita Nanda, Barbara A. Parker, Brian Datnow, Gregor Krings, Shi Wei, Mi...> ;JAMA Oncology. 2021 Sep 16
5 citations
Efficacy of tucatinib for HER2-positive metastatic breast cancer after HER2-targeted therapy: a network meta-analysis.
Kendra DeBusk, Shaun Abeysinghe, Adrian Vickers, Anubhav Nangia, Judith Bell, Chiemeka Ike, Andres Forero-Torres, Matthew T Blahna> ;Future Oncology. 2021 Aug 31
18 citations
Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study.
Andrew M. Evens, Joseph M. Connors, Anas Younes, Stephen M. Ansell, Won Seog Kim, John Radford, Tatyana Feldman, Joseph Tuscano, Kerry J. Savage, Yasuhiro Oki, Andrew ...> ;Haematologica. 2021 Jun 24
14 citations
Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Tr...
Kathryn J. Ruddy, Yue Zheng, Nabihah Tayob, Jiani Hu, Chau T. Dang, Denise A. Yardley, Steven J. Isakoff, Vicente Valero, Meredith Faggen, Therese M. Mulvey, Ron Bose,...> ;Breast Cancer Research and Treatment. 2021 Jun 12
117 citations
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial
Lajos Pusztai, Christina Yau, Denise M. Wolf, Hyo S. Han, Lili Du, Anne M. Wallace, Erica String-Reasor, Judy C. Boughey, A. Jo Chien, Anthony D. Elias, Heather Beckwi...> ;Cancer Cell. 2021 Jul 12
64 citations
Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial
Sara M. Tolaney, Nabihah Tayob, Chau T. Dang, Denise A. Yardley, Steven J. Isakoff, Vicente Valero, Meredith Faggen, Therese M. Mulvey, Ron Bose, Jiani Hu, Douglas Wec...> ;Journal of Clinical Oncology. 2021 Jun 2
1 citations
Economic burden of central nervous system metastases in human epidermal growth factor receptor 2-positive breast cancer.
Naomi Rm Schwartz, Kendra DeBusk, Andres Forero-Torres, Joseph Feliciano, Vamshi Ruthwik Anupindi, Jason Yeaw, Ali McBride> ;Future Oncology. 2021 May 28
25 citations
Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer (“METRIC”): a randomized multicenter study
Linda T. Vahdat, Peter Schmid, Andres Forero-Torres, Kimberly L. Blackwell, Melinda L. Telli, Michelle E. Melisko, Volker Möbus, Javier Cortes, Alberto J. Montero, Cyn...> ;NPJ Breast Cancer. 2021 May 20
9 citations
FOXA1 and adaptive response determinants to HER2 targeted therapy in TBCRC 036.
Steven P. Angus, Timothy J. Stuhlmiller, Gaurav Mehta, Samantha M. Bevill, Daniel R. Goulet, J. Felix Olivares-Quintero, Michael P. East, Maki Tanioka, Jon S. Zawistow...> ;NPJ Breast Cancer. 2021 May 12
24 citations
An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer.
Erica Stringer-Reasor, Jori E. May, Eva Olariu, Valerie Caterinicchia, Yufeng Li, Dongquan Chen, Deborah L. Della Manna, Gabrielle B. Rocque, Christos Vaklavas, Carla ...> ;Breast Cancer Research. 2021 Mar 4
16 citations
Phase Ib Study of Ribociclib plus Fulvestrant and Ribociclib plus Fulvestrant plus PI3K Inhibitor (Alpelisib or Buparlisib) for HR+ Advanced Breast Cancer.
Sara M. Tolaney, Young-Hyuck Im, Emiliano Calvo, Yen-Shen Lu, Erika Hamilton, Andres Forero-Torres, Thomas Bachelot, Michela Maur, Angelica Fasolo, Ralph Tiedt, Lisa N...> ;Clinical Cancer Research. 2021 Jan 15
79 citations
A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma
Nancy L. Bartlett, Alex F. Herrera, Eva Domingo-Domenech, Amitkumar Mehta, Andres Forero-Torres, Ramón García-Sanz, Philippe Armand, Sumana Devata, Antonia Rodriguez I...> ;Blood. 2020 Nov 19
14 citations
Use of 18F-FDG PET/CT as an Initial Staging Procedure for Stage II-III Breast Cancer: A Multicenter Value Analysis
Colby J. Hyland, Flora Varghese, Christina Yau, Heather Beckwith, Katia E. Khoury, William Varnado, Gillian L. Hirst, Robert R. Flavell, A. Jo Chien, Douglas Yee, Clau...> ;Journal of the National Comprehensive Cancer Network. 2020 Nov 2
Join now to see all

Abstracts/Posters

Brentuximab Vedotin with Chemotherapy for Stage 3/4 Classical Hodgkin Lymphoma (cHL): 4-Year Update of the Echelon-1 Study
Andres Forero-Torres, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

A Phase 1b Study Investigating the Combination of the Tetravalent Bispecific NK Cell Engager AFM13 and Pembrolizumab in Patients with Relapsed/Refractory Hodgkin Lymph...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Phase Ib study of gedatolisib in combination with palbociclib and endocrine therapy (ET) in women with estrogen receptor (ER) positive (+) metastatic breast cancer (MB...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

Older Patients with Hodgkin Lymphoma Benefit from Treatment with Brentuximab VedotinOctober 7th, 2015
PI3Kδ and JAK1 Inhibitors Show Promise in Advanced Hodgkin LymphomaJune 19th, 2015